menu
    • menu
    [{"orgOrder":0,"company":"CYPRESS BIOSCIENCE","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"CYPRESS BIOSCIENCE","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CYPRESS BIOSCIENCE \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"CYPRESS BIOSCIENCE \/ CYPRESS BIOSCIENCE"},{"orgOrder":0,"company":"CYPRESS BIOSCIENCE","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"CYPRESS BIOSCIENCE","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CYPRESS BIOSCIENCE \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"CYPRESS BIOSCIENCE \/ CYPRESS BIOSCIENCE"},{"orgOrder":0,"company":"CYPRESS BIOSCIENCE","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Milnacipran","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"CYPRESS BIOSCIENCE","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CYPRESS BIOSCIENCE \/ CYPRESS BIOSCIENCE","highestDevelopmentStatusID":"11","companyTruncated":"CYPRESS BIOSCIENCE \/ CYPRESS BIOSCIENCE"}]

    Find Clinical Drug Pipeline Developments & Deals by CYPRESS BIOSCIENCE

    Menu

    CYPRESS BIOSCIENCE

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CYPRESS BIOSCIENCE

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            CYPRESS BIOSCIENCE

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milnacipran

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : Forest Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

                            Details : Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fibromyalgia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2011

                            Lead Product(s) : Milnacipran

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : Forest Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CYPRESS BIOSCIENCE

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            CYPRESS BIOSCIENCE

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milnacipran

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : Forest Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

                            Details : Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fibromyalgia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2011

                            Lead Product(s) : Milnacipran

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : Forest Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CYPRESS BIOSCIENCE

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            CYPRESS BIOSCIENCE

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milnacipran

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Recipient : Forest Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

                            Details : Milnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fibromyalgia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 01, 2010

                            Lead Product(s) : Milnacipran

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Recipient : Forest Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth